Sight Sciences, Inc. — Earnings Quality Grade F
SGHT · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 46 days, change -3 days YoY
AR growth -9.7% vs revenue growth -3.1%
Revenue -3.1%, CFFO -32.9%. Cash follows revenue
Expense Quality
Inventory growth 22.8% exceeds COGS -7.6%
CapEx growth -41.8% vs revenue -3.1%. Normal
SG&A/Gross Profit = 133.7%, exceeds 70%
Gross margin 86.2%, change +0.7pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.0B)
Accruals ratio = -7.6%. Low accruals
Cash $0.1B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -7.2x (<2x). Financial stress
Other assets -5.8% vs revenue -3.1%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
No goodwill
Manipulation Score
M-Score = -2.88 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor SGHT continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25